Skip to content
Research Article Open access CC BY 4.0

Resistant Nephrotic Syndrome: Review of Trials Using ACTH and a Case Series of Six Patients Treated with ACTHar

Jaime Wolf, Vishnu Patel, Rishi Prasad, Geoffrey Teehan

Journal of Advances in Medicine and Medical Research · pp. 1453–1457 · Published 15 Nov 2014

10.9734/BJMMR/2015/13992

Abstract

Nephrotic syndrome (NS) is associated with edema, proteinuria, hyperlipidemia, and an increased risk for deep vein thrombosis. Therapy may include glucocorticoids, immunosuppressive therapy, and/or chemotherapy. Each is associated with significant toxicity. Adrenocorticotrophic hormone (ACTH) has been approved for treating NS since the 1950s. Both the synthetic form of ACTH (cosyntropin-ACTH 1-24) and ACTHar (ACTH1-39), a synthetic gel isolated from porcine pituitary extracts, have been used successfully in treating NS but fewer than 100 published cases of ACTHar therapy are available in the literature. Membranous nephropathy is the best studied entity. Our case series adds six new cases to the literature and strengthens the growing consensus that ACTHar may be effective in treating focal segmental glomerulosclerosis.

Nephrotic syndrome proteinuria ACTHar

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

9

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.